Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: Role of CB1 and CB2 receptors

ACS Chemical Neuroscience

Volumn 3, Issue 5, 2012, Pages 400-406

  Valdeolivas, Sara ^a,b   Satta, Valentina ^a,c   Pertwee, Roger G ^d   Fernández Ruiz, Javier ^a,b   Sagredo, Onintza ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

9 tetrahydrocannabinol; basal ganglia; cannabidiol; CB1 and CB2 receptors; Huntington's disease; malonate; neurodegeneration; neuroprotection; Phytocannabinoids

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONIC ACID; NABIXIMOLS; NEUROTROPHIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DRUG EFFECT; HUNTINGTON CHOREA; IN VIVO STUDY; MICROGLIA; NERVE CELL; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

Δ9-TETRAHYDROCANNABINOL; BASAL GANGLIA; CANNABIDIOL; CB1 AND CB2 RECEPTORS; HUNTINGTON'S DISEASE; MALONATE; NEURODEGENERATION; NEUROPROTECTION; PHYTOCANNABINOIDS;

ANIMALS; CANNABINOIDS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUNTINGTON DISEASE; INFLAMMATION; MALE; MALONATES; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

CANNABIS; RATTUS;

EID: 84862077856     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn200114w     Document Type: Conference Paper

References (27)

1. Roze, E., Bonnet, C., Betuing, S., and Caboche, J. (2010) Huntington's disease Adv. Exp. Med. Biol. 685, 45-63
2. Zuccato, C., Valenza, M., and Cattaneo, E. (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease Physiol. Rev. 90, 905-981
3. Johnson, C. D. and Davidson, B. L. (2010) Huntington's disease: progress toward effective disease-modifying treatments and a cure Hum. Mol. Genet. 19, R98-R102
4. Pazos, M. R., Sagredo, O., and Fernández-Ruiz, J. (2008) The endocannabinoid system in Huntington's disease Curr. Pharm. Des. 14, 2317-2325
5. Fernández-Ruiz, J., García, C., Sagredo, O., Gómez-Ruiz, M., and de Lago, E. (2010) The endocannabinoid system as a target for the treatment of neuronal damage Expert Opin. Ther. Targets 14, 387-404
6. Lastres-Becker, I., Bizat, N., Boyer, F., Hantraye, P., Fernández-Ruiz, J., and Brouillet, E. (2004) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo NeuroReport 15, 2375-2379 (Pubitemid 39488923)
7. Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., and Fernández-Ruiz, J. (2007) Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors Eur. J. Neurosci. 26, 843-851 (Pubitemid 47274613)
8. Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M. R., Resel, E., Palazuelos, J., Julien, B., Salazar, M., Börner, C., Benito, C., Carrasco, C., Diez-Zaera, M., Paoletti, P., Díaz-Hernández, M., Ruiz, C., Sendtner, M., Lucas, J. J., de Yébenes, J. G., Marsicano, G., Monory, K., Lutz, B., Romero, J., Alberch, J., Ginés, S., Kraus, J., Fernández-Ruiz, J., Galve-Roperh, I., and Guzmán, M. (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease Brain 134, 119-136
9. Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., Fernández-Ruiz, J., Guzmán, M., and Galve-Roperh, I. (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity Brain 132, 3152-3164
10. Sagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres-Becker, I., Romero, J. P., Tolón, R. M., Mechoulam, R., Brouillet, E., Romero, J., and Fernández-Ruiz, J. (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease Glia 57, 1154-1167
11. Pintor, A., Tebano, M. T., Martire, A., Grieco, R., Galluzzo, M., Scattoni, M. L., Pezzola, A., Coccurello, R., Felici, F., Cuomo, V., Piomelli, D., Calamandrei, G., and Popoli, P. (2006) The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum Neuropharmacology 51, 1004-1012 (Pubitemid 44528606)
12. Dowie, M. J., Howard, M. L., Nicholson, L. F., Faull, R. L., Hannan, A. J., and Glass, M. (2010) Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice Neuroscience 170, 324-336
13. Sastre-Garriga, J., Vila, C., Clissold, S., and Montalban, X. (2011) THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis Expert Rev. Neurother. 11, 627-637
14. Zajicek, J. P. and Apostu, V. I. (2011) Role of cannabinoids in multiple sclerosis CNS Drugs 25, 187-201
15. Pertwee, R. G. (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines Br. J. Pharmacol. 156, 397-411
16. Sagredo, O., Pazos, M. R., Satta, V., Ramos, J. A., Pertwee, R. G., and Fernández-Ruiz, J. (2011) Neuroprotective effects of phytocannabinoid- based medicines in experimental models of Huntington's disease J. Neurosci. Res. 89, 1509-1518
17. Pouladi, M. A., Xie, Y., Skotte, N. H., Ehrnhoefer, D. E., Graham, R. K., Kim, J. E., Bissada, N., Yang, X. W., Paganetti, P., Friedlander, R. M., Leavitt, B. R., and Hayden, M. R. (2010) Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression Hum. Mol. Genet. 19, 1528-1538
18. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. (1991) Controlled clinical trial of cannabidiol in Huntington's disease Pharmacol., Biochem. Behav. 40, 701-708
19. Curtis, A. and Rickards, H. (2006) Nabilone could treat chorea and irritability in Huntington's disease J. Neuropsychiatry Clin. Neurosci. 18, 553-554 (Pubitemid 44713898)
20. Curtis, A., Mitchell, I., Patel, S., Ives, N., and Rickards, H. (2009) A pilot study using nabilone for symptomatic treatment in Huntington's disease Mov. Disord. 24, 2254-2259
21. Müller-Vahl, K. R., Schneider, U., and Emrich, H. M. (1999) Nabilone increases choreatic movements in Huntington's disease Mov. Disord. 14, 1038-1040
22. Saleh, N., Moutereau, S., Azulay, J. P., Verny, C., Simonin, C., Tranchant, C., El Hawajri, N., Bachoud-Lévi, A. C., Maison, P., and Huntington French Speaking Group (2010) High insulin-like growth factor I is associated with cognitive decline in Huntington disease Neurology 75, 57-63
23. Pavese, N., Gerhard, A, Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., and Piccini, P. (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study Neurology 66, 1638-1643 (Pubitemid 43964614)
24. Russo, E. and Guy, G. W. (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Med. Hypotheses 66, 234-246 (Pubitemid 41773895)
25. Lastres-Becker, I., Bizat, N., Boyer, F., Hantraye, P., Brouillet, E., and Fernández-Ruiz, J. (2003) Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate NeuroReport 14, 813-816 (Pubitemid 36667917)
26. Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R. M., Ramos, J. A., and Guzmán, M. (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28, 39-45 (Pubitemid 46038536)
27. Alvarez, F. J., Lafuente, H., Rey-Santano, M. C., Mielgo, V. E., Gastiasoro, E., Rueda, M., Pertwee, R. G., Castillo, A. I., Romero, J., and Martínez-Orgado, J. (2008) Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets Pediatr. Res. 64, 653-658